A serum-free culture medium for γδT cells and its application

By adding TWS119, MnTBAP chloride, DL-α-tocopherol acetate and IL-2 in the γδT cell culture medium, the problems of difficulty in amplification of γδT cell and serum dependence in the prior art were solved, and efficient Improved γδT cell culture and tumor cell killing efficiency.

CN118703437BActive Publication Date: 2024-12-03GENETIMES EXCELL TECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411179134.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-03
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

The prior art is difficult to effectively amplify γδ T cells, and it relies on serum or serum substitutes, resulting in high cost and batch differences, limiting the application of γδ T cells in tumor cell therapy and immune cell therapy.

Method used

Provide a serum-free culture medium of γδ T cells. The added complex formed by adding TWS119, MnTBAP chloride, DL-α-tocopherol acetate and IL-2 to the basal culture medium can significantly improve the proliferation of γδ T cells and Survival rate avoids dependence on serum or serum surrogate.

Benefits of technology

The high cell viability, proliferation fold and CAR transfer efficiency of γδT cells have been improved, and the killing efficiency of tumor cells has been improved. It is suitable for scientific research and clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and in particular to a serum-free medium for γδT cells and its application, wherein the medium includes a basal medium and an added complex, wherein the basal medium is any one of an X-Vivo15 medium or a KBM581 medium; the added complex includes: TWS119 with a final concentration of 0.5-5 μM / L, MnTBAP chloride with a final concentration of 1-10 μM / L, DL-α-tocopherol acetate with a final concentration of 0.5-2 mg / L, and zoledronic acid with a final concentration of 1-20 μM / L. The culture medium of the present invention cultivates γδT cells without the need for additional addition of serum or serum substitutes, can significantly improve the γδT cell expansion multiple, and can improve the transduction efficiency of CAR into γδT cells, while having good CAR-γδT cell killing tumor cell efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a γδT cell serum-free culture medium and an application thereof. Background Art

[0002] TCR (T cell receptor) is a specific receptor for T cells to recognize protein antigens. According to the difference in TCR types, T cells can be classified into αβT cells and γδT cells. Generally speaking, T cells actually refer to αβT cells, which account for 65% to 70% of the T cell population, while γδT cells, as an important subpopulation of T cells, account for 0.5% to 5% of all T lymphocytes, and their TCRs are composed of γ chain and δ chain. γδT cells are natural surveillance cells of the immune system. They patrol the human body constantly and can recognize target antigens without being restricted by the major histocompatibility complex (MHC), and mediate anti-tumor responses without causing graft versus host disease (GvHD). They are considered to be an ideal source of allogeneic cell therapy. γδT cells can achieve anti-tumor purposes directly or indirectly. At the same time, γδT cells are also important early source cells for secreting cytokines (such as IFN-γ and TNF-α). Both IFN-γ and TNF-α inhibit cancer growth through multiple mechanisms. γδT cells can also exert their indirect anti-tumor effects by interacting with B cells, DC cells, αβT cells and NK cells, respectively. At present, the most commonly used method to expand γδT cells is to use small molecule bisphosphonates, antibodies and the like to selectively activate γδT cells. The traditional method starts with PBMC, adds zoledronic acid and IL-2 to the culture medium, and often needs to add serum or serum substitutes to promote its expansion, otherwise a large number of γδT cells cannot be obtained, and it is difficult to use them for large-scale preparation of γδT cells. Serum or serum substitutes are expensive, the composition is unknown, and there are batch differences; therefore, how to provide a serum-free culture medium that can significantly increase the expansion multiple of γδT cells for the preparation of γδT cells, thereby improving the role of γδT cells in tumor cell therapy and immune cell therapy, has become a problem to be solved. Summary of the invention

[0003] In order to solve the technical problems mentioned in the background technology, the present invention provides a serum-free culture medium for γδT cells and its application, and the technical solution is:

[0004] A γδT cell serum-free culture medium comprises a basal culture medium and an additive complex, wherein the additive complex consists of TWS119 with a final concentration of 0.5-5 μM / L, MnTBAP chloride with a final concentration of 1-10 μM / L, DL-α-tocopherol acetate with a final concentration of 0.5-2 mg / L, zoledronic acid with a final concentration of 1-20 μM / L, and 1500 IU / mL IL-2.

[0005] Preferably, the added complex consists of TWS119 with a final concentration of 2 μM / L, MnTBAP chloride with a final concentration of 3 μM / L, DL-α-tocopherol acetate with a final concentration of 1 mg / L, zoledronic acid with a final concentration of 6 μM / L, and 1500 IU / mL IL-2.

[0006] Preferably, the basal culture medium is any one of X-Vivo15 T cell serum-free culture medium or KBM581 lymphocyte serum-free culture medium.

[0007] A use of a γδT cell serum-free culture medium, comprising any one of the aforementioned γδT cell serum-free culture mediums, for obtaining γδT cells.

[0008] The beneficial effects of the present invention are mainly that: the present invention cultivates γδT cells by adding TWS119, MnTBAP chloride, DL-α-tocopherol acetate, IL-2, and zoledronic acid to the basal culture medium, without the need to add serum or serum substitutes. The γδT cells obtained by the culture medium of the present invention have high cell viability, high expansion multiples, high transduction efficiency of CAR into γδT cells, high efficiency of killing tumor cells, and are suitable for further scientific research and clinical application research.

[0009] Mechanism of action of the present invention: TWS119 significantly enhances the proliferation and survival of γδT cells by activating the rapamycin target (mTOR) pathway, upregulating the expression of the anti-apoptotic protein Bcl-2, and inhibiting cleaved caspase-3. TWS119 increases the expression level of granzyme B in a dose-dependent manner and can enhance the cytolytic activity of γδT cells against tumor cells in vitro. MnTBAP chloride is a manganese porphyrin complex and a superoxide scavenger with antioxidant properties. After CAR is transferred into γδT cells, it can protect cells from death and quickly restore viability. Tocopherol is a fat-soluble antioxidant that protects cell membranes from oxidative damage and maintains a high viability of activated T cells. DETAILED DESCRIPTION

[0010] The technical solution of the present invention will be further described below in conjunction with specific embodiments. The technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0011] 1. Experimental materials:

[0012] TWS119 (Manufacturer: Shanghai Haoyuan, Catalog No. HY-10590), MnTBAP chloride (Manufacturer: Aladdin, Catalog No. M275804), DL-α-tocopherol acetate (Manufacturer: Sigma, Catalog No. T3376), rhIL-2 (abbreviated as IL-2) (Manufacturer: Near Shore Protein, Catalog No. GMP-CD66), Zoledronic acid (Manufacturer: Sigma, Catalog No. 1724827), X-Vivo15 T cell serum-free medium (manufacturer: Lonza, catalog number 04-418Q), KBM581 lymphocyte serum-free medium (manufacturer: Corning, catalog number 88-581-CM), fetal bovine serum (FBS) (Ecosai Biotechnology, FSP500), CD3-PerCP-Cy5.5 antibody (Baijin Biotechnology, catalog number 300430), TCRVγ9-FITC antibody (Baijin Biotechnology, catalog number 331306), Vδ2-APC antibody (Baijin Biotechnology, catalog number 331418); other methods and reagents used in this example are conventional methods and reagents in the art unless otherwise specified.

[0013] 2. Experimental methods:

[0014] (1) γδT cell culture and lentiviral transduction:

[0015] PBMCs were freshly isolated from human whole blood using density centrifugation for activation and expansion of γδT cells. On day 0 (D0), the isolated PBMCs were cultured in T cell culture medium supplemented with the complex of the present invention and 1500 IU / mL IL-2 to adjust the cell density to 2×10 6 / mL, inoculated in a 12-well plate, and placed in a 37°C, 5% carbon dioxide incubator for cell activation. On day 1 (D1), add lentivirus at an MOI of 3 (one cell corresponds to 3 viruses); on day 3, transfer the cells to a six-well plate and add 2mL of culture medium; every 2 days thereafter, take samples and count them to maintain a 1×10 6 The cells were cultured at a density of 100 cells / mL.

[0016] (2) Detection of cell viability and proliferation efficiency of γδT cells:

[0017] Samples were taken for counting on the 3rd (D3), 5th (D5), 7th (D7), 9th (D9), and 11th (D11) days of culture. During the culture process, the cells were mixed evenly, sampled, stained with AO / PI, and counted to obtain cell viability and cell proliferation multiples.

[0018] (3) γδT cell transduction efficiency detection:

[0019] Under the above culture conditions, the cell transduction efficiency was tested on the 11th day of culture. 6 The cells were centrifuged at 400 g for 5 minutes, the supernatant was removed and washed once with 1 mL PBS, resuspended in 0.5 mL PBS, and analyzed by flow cytometry. The negative control was 1.0 × 10 cells that were not transduced. 6 The cells were analyzed by flow cytometry after the same operation.

[0020] (4) Identification of γδT cell subtypes:

[0021] Under the above culture conditions, the γδT cell subtypes were detected on the 11th day of culture, and the CD3-PerCP-Cy5.5 antibody, TCRVγ9-FITC antibody, and Vδ2-APC antibody were used to detect the proportion of CD3-positive and TCRVγ9Vδ2-positive cells.

[0022] (5) CAR-γδT cell toxicity detection:

[0023] Under the above culture conditions, cytotoxicity was detected on the 11th day of culture. Using the B cell malignant tumor cell line Raji as the target cell, a co-culture system of CAR-T cells and targeted tumor cells was established according to different E:T (effector cell: target cell) ratios. The biological efficacy of CAR-T was evaluated by detecting the tumor cell killing rate, and a control system of co-culture of untransduced γδT cells and tumor cells was established.

[0024] Example 1: Using X-Vivo 15 as the basic culture medium, different additives were added into the X-Vivo 15 culture medium, and each experimental group was set up as follows:

[0025] M1 (TWS119): TWS119 was added to X-Vivo15 medium, and the concentration was set to 2 μM / L;

[0026] M2 (MnTBAP chloride): MnTBAP chloride was added to X-Vivo15 medium and the concentration was set to 3 μM / L;

[0027] M3 (DL-α-tocopheryl acetate): DL-α-tocopheryl acetate was added to X-Vivo15 medium at a concentration of 1 mg / L;

[0028] M4 (zoledronic acid): zoledronic acid was added to X-Vivo15 medium and the concentration was set to 6 μM / L;

[0029] M5 (FBS): Add FBS to X-Vivo15 medium at a ratio of 10%;

[0030] M6 (complex combination): TWS119 was added to X-Vivo15 medium at a final concentration of 2 μM / L, MnTBAP chloride was added to a final concentration of 3 μM / L, DL-α-tocopheryl acetate was added to a final concentration of 1 mg / L, and zoledronic acid was added to a final concentration of 6 μM / L.

[0031] The test results are as follows:

[0032] 1. Cell viability of T cells, the data are shown in Table 1 below:

[0033] The data showed that the cell viability of the M6 ​​experimental group recovered rapidly after D5, and reached a maximum of 95% on D11, which was better than other schemes.

[0034] Table 1

[0035]

[0036] 2. The proliferation multiples of T cells, the experimental results are shown in Table 2:

[0037] Table 2

[0038]

[0039] At D11, the cell doublings of the M1 experimental group were 832.66, the M2 experimental group were 802.63, the M3 experimental group were 869.55, the M4 experimental group were 432.66, the M5 experimental group were 324.33, and the M6 ​​experimental group were 1835.98. Therefore, the compounds of the present invention are helpful to increase the proliferation times of γδT cells, among which the complex combination of the M6 ​​experimental group has the best effect on enhancing cell proliferation.

[0040] 3. The transduction positive rate of T cells. The experimental results are shown in Table 3:

[0041] Table 3

[0042]

[0043] At D11, the transduction efficiency of the M1 experimental group was 31.2%, the transduction efficiency of the M2 experimental group was 35.3%, the transduction efficiency of the M3 experimental group was 32.6%, the transduction efficiency of the M4 experimental group was 17.1%, the transduction efficiency of the M5 experimental group was 13.7%, and the transduction efficiency of the M6 ​​experimental group was 69.5%. Therefore, the compounds of the present invention can improve the transduction efficiency of T cells, among which the M6 ​​experimental group complex combination has the best effect of improving the transduction efficiency.

[0044] 4. Identification of T cell subtypes. The experimental results are shown in Table 4:

[0045] Table 4

[0046]

[0047] At D11, the γδT positive rate of the M1 experimental group was 61.2%, the γδT positive rate of the M2 experimental group was 55.3%, the γδT positive rate of the M3 experimental group was 52.6%, the γδT positive rate of the M4 experimental group was 33.1%, the γδT positive rate of the M5 experimental group was 21.7%, and the γδT positive rate of the M6 ​​experimental group was 91.5%. Therefore, the compound of the present invention can improve the purity of γδ cells, among which the M6 ​​experimental group complex combination has the best effect on improving the purity of γδT cells.

[0048] 5. CAR-γδT cell toxicity test. The experimental results are shown in Table 5:

[0049] Table 5

[0050]

[0051] Under the condition of E:T=9:1, the specific killing rate of tumor cells in the M1 experimental group was 37.66%, the specific killing rate of tumor cells in the M2 experimental group was 39.99%, the specific killing rate of tumor cells in the M3 experimental group was 38.69%, the specific killing rate of tumor cells in the M4 experimental group was 31.22%, the specific killing rate of tumor cells in the M5 experimental group was 23.67%, and the specific killing rate of tumor cells in the M6 ​​experimental group was 67.66%. Therefore, the compounds in the present invention can improve the killing efficiency of CAR-γδT cells, among which the killing efficiency improvement effect of the M6 ​​experimental group complex combination is the best.

[0052] Example 2: Using X-Vivo 15 as the basic culture medium, different additives were added into the X-Vivo 15 culture medium, and each experimental group was set up as follows:

[0053] The first group is a low-concentration additive complex combination of the present invention: TWS119 is added to X-Vivo15 medium at a final concentration of 0.5 μM / L, MnTBAP chloride is added to a final concentration of 1 μM / L, DL-α-tocopherol acetate is added to a final concentration of 0.5 mg / L, and zoledronic acid is added to a final concentration of 1 μM / L;

[0054] The second group is a medium concentration addition complex combination of the present invention: TWS119 is added to X-Vivo15 medium at a final concentration of 2 μM / L, MnTBAP chloride is added to a final concentration of 3 μM / L, DL-α-tocopherol acetate is added to a final concentration of 1 mg / L, and zoledronic acid is added to a final concentration of 6 μM / L;

[0055] The third group is a high-concentration additive complex combination of the present invention: TWS119 is added to X-Vivo15 medium at a final concentration of 5 μM / L, MnTBAP chloride is added to a final concentration of 10 μM / L, DL-α-tocopherol acetate is added to a final concentration of 2 mg / L, and zoledronic acid is added to a final concentration of 20 μM / L;

[0056] The fourth group was a control without added complexes, containing only X-Vivo15 medium;

[0057] The fifth group was the FBS-added control, in which 10% FBS was added to the X-Vivo15 medium.

[0058] The test results are as follows:

[0059] 1. Cell viability of T cells, the data are shown in Table 6 below:

[0060] The data showed that under the condition of adding the complex at a medium concentration in the second group, the cell viability recovered fastest after D5, and reached a maximum of 95% on D11, which was better than other solutions.

[0061] Table 6

[0062]

[0063] 2. The proliferation multiples of T cells, the experimental results are shown in Table 7:

[0064] Table 7

[0065]

[0066] At D11, the cell doublings of the first group were 1243.4, the second group were 1835.98, the third group were 987.45, the fourth group were 176.5, and the fifth group were 324.33. Therefore, the addition of the complex at a medium concentration in the second group had the best effect on promoting cell proliferation.

[0067] 3. The transduction positive rate of T cells, the experimental results are shown in Table 8:

[0068] Table 8

[0069]

[0070] At D11, the transduction efficiency of the first group was 54%, the second group was 69.5%, the third group was 49%, the fourth group was 8.3%, and the fifth group was 13.7%. Therefore, the condition of adding complexes at a medium concentration in the second group had the best effect on improving the transduction efficiency.

[0071] 4. Identification of T cell subtypes. The experimental results are shown in Table 9:

[0072] Table 9

[0073]

[0074] At D11, the positive rate of γδT in the first group was 76%, the positive rate of γδT in the second group was 91.5%, the positive rate of γδT in the third group was 71%, the positive rate of γδT in the fourth group was 15%, and the positive rate of γδT in the fifth group was 21.7%. Therefore, the condition of adding complexes at a medium concentration in the second group had the best effect on improving the purity of γδT cells.

[0075] 5. CAR-γδT cell toxicity test. The experimental results are shown in Table 10:

[0076] Table 10

[0077]

[0078] Under the condition of E:T=9:1, the specific killing rate of the first group against tumor cells was 43.89%, the specific killing rate of the second group against tumor cells was 67.66%, the specific killing rate of the third group against tumor cells was 39.7%, the specific killing rate of the fourth group against tumor cells was 14.64%, and the specific killing rate of the fifth group against tumor cells was 23.67%. Therefore, the condition of adding the complex at a medium concentration in the second group has the best effect on improving the killing efficiency.

[0079] Example 3: Using Corning KBM581 as the basic culture medium, different additives were added into the KBM581 culture medium. The settings of each experimental group were as follows:

[0080] M1 (TWS119): TWS119 was added to KBM581 medium, and the concentration was set to 2 μM / L;

[0081] M2 (MnTBAP chloride): MnTBAP chloride was added to KBM581 culture medium and the concentration was set to 3 μM / L;

[0082] M3 (DL-α-tocopherol acetate): DL-α-tocopherol acetate was added to KBM581 medium, and the concentration was set to 1 mg / L;

[0083] M4 (zoledronic acid): zoledronic acid was added to KBM581 medium and the concentration was set to 6 μM / L;

[0084] M5 (FBS): Add FBS to KBM581 medium at a ratio of 10%;

[0085] M6 (complex combination): TWS119 was added to KBM581 medium at a final concentration of 2 μM / L, MnTBAP chloride was added to a final concentration of 3 μM / L, DL-α-tocopheryl acetate was added to a final concentration of 1 mg / L, and zoledronic acid was added to a final concentration of 6 μM / L.

[0086] The test results are as follows:

[0087] 1. Cell viability of T cells, the data are shown in Table 11 below:

[0088] The data showed that the cell viability of the M6 ​​experimental group recovered rapidly after D5, and reached a maximum of 93% on D11, which was better than other schemes.

[0089] Table 11

[0090]

[0091] 2. The proliferation multiples of T cells, the experimental results are shown in Table 12:

[0092] Table 12

[0093]

[0094] At D11, the cell doublings of the M1 experimental group were 734.93, the M2 experimental group were 702.63, the M3 experimental group were 769.57, the M4 experimental group were 432.66, the M5 experimental group were 224.33, and the M6 ​​experimental group were 1578.96. Therefore, the compounds of the present invention help to increase the proliferation times of γδT cells, among which the M6 ​​experimental group complex combination has the best effect on cell proliferation enhancement.

[0095] 3. The transduction positive rate of T cells. The experimental results are shown in Table 13:

[0096] Table 13

[0097]

[0098] At D11, the transduction efficiency of the M1 experimental group was 29.2%, the transduction efficiency of the M2 experimental group was 32.3%, the transduction efficiency of the M3 experimental group was 30.6%, the transduction efficiency of the M4 experimental group was 15.1%, the transduction efficiency of the M5 experimental group was 14.7%, and the transduction efficiency of the M6 ​​experimental group was 59.5%. Therefore, the compounds of the present invention can improve the transduction efficiency of T cells, among which the M6 ​​experimental group complex combination has the best effect of improving the transduction efficiency.

[0099] 4. Identification of T cell subtypes. The experimental results are shown in Table 14:

[0100] Table 14

[0101]

[0102] At D11, the γδT positive rate of the M1 experimental group was 54.2%, the γδT positive rate of the M2 experimental group was 50.3%, the γδT positive rate of the M3 experimental group was 49.6%, the γδT positive rate of the M4 experimental group was 29.1%, the γδT positive rate of the M5 experimental group was 15.7%, and the γδT positive rate of the M6 ​​experimental group was 87.5%. Therefore, the compound of the present invention can improve the purity of γδ cells, among which the M6 ​​experimental group complex combination has the best effect on improving the purity of γδ cells.

[0103] 5. CAR-γδT cell toxicity test. The experimental results are shown in Table 15:

[0104] Table 15

[0105]

[0106] Under the condition of E:T=9:1, the specific killing rate of tumor cells in the M1 experimental group was 33.65%, the specific killing rate of tumor cells in the M2 experimental group was 31.99%, the specific killing rate of tumor cells in the M3 experimental group was 33.69%, the specific killing rate of tumor cells in the M4 experimental group was 27.22%, the specific killing rate of tumor cells in the M5 experimental group was 19.67%, and the specific killing rate of tumor cells in the M6 ​​experimental group was 60.97%. Therefore, the compounds in the present invention can improve the killing efficiency of CAR-γδT cells, among which the M6 ​​experimental group has the best effect in improving the killing efficiency of the complex combination.

[0107] Example 4: Using Corning KBM581 as the basic culture medium, different additives were added into the KBM581 culture medium. The settings of each experimental group were as follows:

[0108] The first group is a low-concentration additive complex combination of the present invention: TWS119 is added to the KBM581 medium at a final concentration of 0.5 μM / L, MnTBAP chloride is added to a final concentration of 1 μM / L, DL-α-tocopherol acetate is added to a final concentration of 0.5 mg / L, and zoledronic acid is added to a final concentration of 1 μM / L;

[0109] The second group is a medium concentration addition complex combination of the present invention: TWS119 is added to the KBM581 medium at a final concentration of 2 μM / L, MnTBAP chloride is added to a final concentration of 3 μM / L, DL-α-tocopherol acetate is added to a final concentration of 1 mg / L, and zoledronic acid is added to a final concentration of 6 μM / L;

[0110] The third group is a high-concentration additive complex combination of the present invention: TWS119 is added to the KBM581 medium at a final concentration of 5 μM / L, MnTBAP chloride is added to a final concentration of 10 μM / L, DL-α-tocopherol acetate is added to a final concentration of 2 mg / L, and zoledronic acid is added to a final concentration of 20 μM / L;

[0111] The fourth group was a control without added complex, containing only KBM581 medium;

[0112] The fifth group was a control group with FBS added, in which 10% FBS was added to the KBM581 culture medium.

[0113] The test results are as follows:

[0114] 1. Cell viability of T cells, the data are shown in Table 16 below:

[0115] The data showed that under the condition of adding the complex at a medium concentration in the second group, the cell viability recovered fastest after D5, and reached a maximum of 95% on D11, which was better than other solutions.

[0116] Table 16

[0117]

[0118] 2. The proliferation multiples of T cells, the experimental results are shown in Table 17:

[0119] Table 17

[0120]

[0121] At D11, the cell doublings of the first group were 879.3, the second group were 1578.96, the third group were 743.9, the fourth group were 243.45, and the fifth group were 324.33. Therefore, the condition of adding the complex at a medium concentration in the second group had the best effect on promoting cell proliferation.

[0122] 3. The transduction positive rate of T cells. The experimental results are shown in Table 18:

[0123] Table 18

[0124]

[0125] At D11, the transduction efficiency of the first group was 43.78%, the second group was 59.5%, the third group was 40.76%, the fourth group was 10.76%, and the fifth group was 13.7%. Therefore, the condition of adding complexes at a medium concentration in the second group had the best effect on improving the transduction efficiency.

[0126] 4. Identification of T cell subtypes. The experimental results are shown in Table 19:

[0127] Table 19

[0128]

[0129] At D11, the positive rate of γδT in the first group was 74.97%, the positive rate of γδT in the second group was 87.5%, the positive rate of γδT in the third group was 69.84%, the positive rate of γδT in the fourth group was 19.76%, and the positive rate of γδT in the fifth group was 21.7%. Therefore, the condition of adding complexes at a medium concentration in the second group had the best effect on improving the purity of γδT cells.

[0130] 5. CAR-γδT cell toxicity test. The experimental results are shown in Table 20:

[0131] Table 20

[0132]

[0133] Under the condition of E:T=9:1, the specific killing rate of the first group against tumor cells was 44.89%, the specific killing rate of the second group against tumor cells was 60.97%, the specific killing rate of the third group against tumor cells was 40.19%, the specific killing rate of the fourth group against tumor cells was 16.55%, and the specific killing rate of the fifth group against tumor cells was 23.67%. Therefore, the condition of adding the complex at a medium concentration in the second group has the best effect on improving the killing efficiency.

[0134] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A serum-free culture medium for γδT cells, It is characterized in that It comprises a basic culture medium and an additive complex, wherein the additive complex is composed of TWS119 with a final concentration of 0.5-5 μM / L, MnTBAP chloride with a final concentration of 1-10 μM / L, DL-α-tocopherol acetate with a final concentration of 0.5-2 mg / L, zoledronic acid with a final concentration of 1-20 μM / L, and IL-2 with a final concentration of 1500 IU / mL; The basal culture medium is any one of X-Vivo15 T cell serum-free culture medium or KBM581 lymphocyte serum-free culture medium.

2. A γδT cell serum-free culture medium according to claim 1, It is characterized in that The added complex consists of TWS119 with a final concentration of 2 μM / L, MnTBAP chloride with a final concentration of 3 μM / L, DL-α-tocopherol acetate with a final concentration of 1 mg / L, zoledronic acid with a final concentration of 6 μM / L, and IL-2 with a final concentration of 1500 IU / mL.

3. Application of a serum-free culture medium for γδT cells, It is characterized in that A γδT cell serum-free culture medium comprising any one of claims 1 to 2, used for obtaining γδT cells.